相关实验视频

Updated: Jun 4, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

血栓的组成及其在缺血性中风评估和再血管化治疗中的含义

Juan Marta-Enguita¹, Florencio J D Machado², Josune Orbe³

¹Servicio de Neurología, Hospital Universitario Navarra, Pamplona, Navarra, Spain; Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Guipúzcoa, Spain; Laboratorio Aterotrombosis, CIMA-Universidad de Navarra, IdiSNA, Pamplona, Navarra, Spain; RICORS-ICTUS, ISCIII, Madrid, Spain.

|December 24, 2024

概括

了解缺血性中风血栓形成的生理病理学是开发新疗法的关键. 分析凝块的组成和形成机制提供了有前途的治疗途径.

科学领域:

神经学神经学
生物化学生物化学
病理学病理学病理学

背景情况:

机械血栓切除术通过使血栓检索成为一种先进的缺血性中风治疗方法.
研究恢复的血栓提供了对凝块形成的生理病理过程的见解.

研究的目的:

阐明涉及到缺血性中风血栓形成的复杂机制和组件.
确定影响血栓特征和对再血管化治疗的抗性因素.

主要方法:

对血栓组成的分析,包括纤维素,血小板,红细胞和中性粒细胞外细胞陷 (NETs).
研究免疫和凝血通路的激活,如血小板聚合和·威尔布兰德因子的释放.
检查血栓成分之间的相互关系及其对治疗疗效的影响.

主要成果:

脑卒中血栓表现出不同比例的纤维素/血小板丰富和红细胞丰富的区域.
富含纤维素,NETs和·维勒布兰德因子的保护外通常围绕着血栓.
血栓的组成和结构显著影响对再血管化疗法的耐药性.

结论:

了解血栓的组成部分和形成机制对于开发新的缺血性中风治疗方法至关重要.
针对这些途径有望增强目前的治疗方法并改善患者的治疗结果.

关键词:

这是一种凝固.凝血是凝固的过程.纤维素分析是一种纤维化解是一种纤维化解.一个心脏病的中风.中性粒细胞外细胞陷一次性中风,中风.血栓是因为血栓.这种情况是因为Trombo Trombo.

更多相关视频

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Published on: July 21, 2023

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...